title: Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders?
authors.forename: A
authors.initials: A
authors.lastname: Agazzi
authors.forename: P
authors.initials: P
authors.lastname: Rocca
authors.forename: D
authors.initials: D
authors.lastname: Laszlo
authors.forename: L
authors.initials: L
authors.lastname: Bodei
authors.forename: C
authors.initials: C
authors.lastname: Grana
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: G
authors.initials: G
authors.lastname: Paganelli
mesh_terms: D018951:Antigens, CD20 / Q000097:blood*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives*; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes
chemical_list: D018951:Antigens, CD20; D015021:Yttrium Radioisotopes; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide